Document |
Document Title |
WO/2023/238126A1 |
The present subject matter provides a composition for treating and preventing a variety of diseases that are caused by, or linked to, GABAergic transmission dysfunction, the composition comprising: at least one first agent configured to ...
|
WO/2023/238131A1 |
Methods of treating a neurodevelopmental disorder caused by a mutation in HNRNPH2 or PCDH19, comprising downregulating expression of HNRNPH2 or PCDH19 in cells of the brain of a subject are provided. Antisense oligonucleotides useful in ...
|
WO/2023/235937A1 |
The present disclosure generally relates to the surprising discovery that azabicyclothiophenyl compounds can treat depression in subjects resistant to antidepressant treatments and/or treat depression associated cognitive impairment in s...
|
WO/2023/236778A1 |
The present invention relates to a trifunctional compound, comprising at least one covalent warhead capable of forming a reversible or irreversible covalent linkage with a protein or tissue. The present invention further relates to a pha...
|
WO/2023/240134A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...
|
WO/2023/238955A1 |
The present invention pertains to a method for controlling a membrane potential-dependent ion channel (VGSC or the like) through a type I taste receptor present in a nerve cell or the like. In the present invention, it has been found t...
|
WO/2023/239629A1 |
This disclosure provides compounds and pharmaceutically acceptable salts thereof that are useful as modulators of targeted ubiquitination. The compounds disclosed herein bind to and degrade one or more cyclin dependent kinases 2 (CDK2).
|
WO/2023/239839A1 |
Disclosed herein are compounds having an isoxazole core or an oxadiazole core or a pharmaceutically acceptable salt thereof and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excess...
|
WO/2023/237686A1 |
The present invention relates to a combination comprising vitamin C and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Lactobacillus rhamnosus, when de...
|
WO/2023/238948A1 |
The subject's brain neurogenesis promoter of the present invention contains miR-30a, etc. or a vector which is for expressing miR-30a, etc. in the brain nerves of young and elderly subjects. The present invention also provides an agent f...
|
WO/2023/214314A9 |
The present disclosure relates to the c-Abl inhibitor vodobatinib, or a pharmaceutically acceptable salt thereof, for use in treating, delaying, inhibiting, or suppressing the progression of neurodegenerative diseases, preferably early s...
|
WO/2023/235915A1 |
Described herein are antisense oligonucleotides, vectors, and related compositions and methods for increasing endogenous expression of SHANK3 protein and uses thereof for conditions associated with SHANK3 haploinsufficiency such as Phela...
|
WO/2023/236924A1 |
Provided are a biphenyl compound, a pharmaceutical composition, a method for preparing same, and use thereof. The biphenyl compound has a structure represented by formula I. The provided biphenyl compound can have relatively good binding...
|
WO/2023/237097A1 |
The present invention provides a 19-nor-C3,3-disubstituted C21-azacyclo-substituted steroid and a method for using same. In particular, the present invention relates to a compound represented by general formula (I), a method for preparin...
|
WO/2023/237306A1 |
The present invention relates to a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or compositions comprising the combination, for use in treating and/or preventing stress and/or a mood ...
|
WO/2023/237684A1 |
The present invention relates to a combination comprising vitamin C and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Lactobacillus rhamnosus, when de...
|
WO/2023/240031A1 |
The present invention provides compositions and methods for treating Postural orthostatic tachycardia syndrome (POTS) In some embodiments, the POTS is associated with hypermobility spectrum disorders/hypermobile Ehlers-Danlos syndrome (H...
|
WO/2023/238073A1 |
Provided are methods for treating binge eating disorder (BED) or one or more symptoms thereof, that involve the administration of psychedelics, such as psilocybin, and related uses of the psychedelics. The disclosure in some aspects also...
|
WO/2023/235925A1 |
The present invention provides compounds of Formula (I), which have activity as inhibitors of MERTK. The present invention also provides radio-labelled compounds which may be used in diagnostic and imaging compositions. The present inven...
|
WO/2023/239925A1 |
Provided herein arc compounds of Formula (I- A), (I-B), or (I-C), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically enriched forms, prodrugs, or mixtures thereof, a...
|
WO/2023/237623A1 |
The present invention relates the use of an anti-inflammatory agent for inhibiting and/or preventing damage of a peripheral ganglion in a subject, particularly in a subject suffering from a cardiac disease. The present invention also rel...
|
WO/2023/237682A1 |
The present invention relates to a combination comprising vitamin B2 and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin B2 and Lactobacillus rhamnosus, when ...
|
WO/2023/237753A1 |
The present disclosure relates to crystalline forms of norketamine, in particular norketamine hydrochloride, processes for the preparation and uses thereof.
|
WO/2023/237673A1 |
The present invention relates to a combination comprising vitamin C and Bifidobacterium animalis ssp. lactis and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Bifidobacterium ani...
|
WO/2023/240186A1 |
Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable ph...
|
WO/2023/237305A1 |
The present invention relates to a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or nutritional compositions comprising the combination. The combination or compositions are for use in ...
|
WO/2023/239767A2 |
Compositions and methods for the treatment of a human subject who has had a stroke or myocardial ischemia reperfusion injury, by administering to the subject a pharmaceutical composition including a compound of Formula (I) and/or of Form...
|
WO/2023/237680A1 |
The present invention relates to a combination comprising vitamin C and Bifidobacterium animalis ssp. lactis and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Bifidobacterium ani...
|
WO/2023/240086A1 |
Antibodies or portions thereof specific for human CCKBR, a composition comprising the antibody or portion thereof, an isolated cell expressing the antibody or portion thereof, and a method to inhibit or treat pain by using the antibody o...
|
WO/2023/239908A1 |
The present invention relates to a method of treating a mitochondrial disease in a patient in need thereof by administering Compound (I), a stimulator of soluble guanylate cyclase (sGC) at certain dosages either alone or in combination t...
|
WO/2023/014956A9 |
The present disclosure provides, in part, pharmaceutical compositions comprising radiprodil and pharmaceutically acceptable excipients and methods of use thereof in the treatment of disorders such as epileptic disorders.
|
WO/2023/239729A1 |
The present disclosure is directed to compounds of Formula (I): wherein m, n, Y, R1, R2, R3, R4 and R5 are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable s...
|
WO/2023/240206A2 |
Compositions and methods for modulation by upregulation (up modulation) and/or downregulation (down modulation) of mitophagy are described for the treatment of mitochondrial disorders including OPA-1 related disease and Single Large Scal...
|
WO/2023/237681A1 |
The present invention relates to a combination comprising vitamin C and Bifidobacterium animalis ssp. lactis and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Bifidobacterium ani...
|
WO/2023/237124A1 |
Disclosed are a crocin suspension and use thereof in the preparation of a rapid-acting antidepressant drug. The crocin suspension comprises an active ingredient and an auxiliary material in the following mass ratio: crocin:suspending age...
|
WO/2023/236263A1 |
The present invention provides a benzoxazole derivative, a preparation method therefor, and an application thereof. The benzoxazole derivative provided by the present invention has a structure as represented by formula (I). Experimental ...
|
WO/2023/235864A1 |
Disclosed herein are methods and kits for assessing a. risk of subject developing autism spectrum disorder (ASD). The methods can include determining a level of Limosilactobacillus reuteri in a sample from the subject, or receiving resul...
|
WO/2023/233357A1 |
The disclosure relates to a subcutaneous dosage of Compound (I), or a pharmaceutically acceptable salt thereof, for the treatment of diseases or disorders mediated by negative allosteric modulation or inhibition of NR2B-containing NMDA r...
|
WO/2023/232997A1 |
The invention relates to a synergistic multi-ionic complex providing potentiated preventive and therapeutic responses to inflammation by modulating the pathways of immunity. It is a composition comprising mineral salts, including at leas...
|
WO/2023/232462A1 |
The present application provides a synthetic nutritional composition comprising milk fat globule membrane (MFGM) in the range of about 10 μg/100 kcal to about 1500 mg/100 kcal for use in improving neurological development in a paediatri...
|
WO/2023/233185A1 |
The present invention relates to the field of medicaments. Particularly, the present invention refers to the combination of cannabidiol (CBD) and alpha-lipoic acid at a specific dosage regimen and related application with "entourage effe...
|
WO/2023/231402A1 |
Provided is use of UbV.E4B protein in the preparation of a medicament for promoting central nervous regeneration. The UbV.E4B protein promotes the axonal regeneration of a central nervous system by selectively inhibiting a Ube4b ubiquiti...
|
WO/2023/233277A1 |
The present invention relates to lyophilized pharmaceutical compositions of copper histidinate and one or more pharmaceutically acceptable excipients. It also relates to processes for preparing such compositions.
|
WO/2023/232083A1 |
The present invention belongs to the field of biomedicine, and relates to a beta 2-microglobulin blocking peptide, and a pharmaceutical composition and the use thereof. In particular, the present invention relates to an isolated polypept...
|
WO/2023/235360A1 |
This disclosure provides methods for using a particular class of apelin receptor modulators to reduce blood-brain barrier (BBB) permeability in a subject in need thereof, and in particular methods of treatment for a variety of disorders,...
|
WO/2023/235166A1 |
The present invention relates to crystalline fine particle forms of 6,7-dihydro-4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin-1-yl
)propyl)thieno[2,3-b]pyridine-5-carboxamide potassium salt (PRX-3140) for particle delivery systems (PDS) wi...
|
WO/2023/233791A1 |
Provided are: an integrin activator that contains a substance that inhibits binding between a fibronectin and an immune inhibitory receptor LILRB4 as an active ingredient; and a therapeutic agent that contains a substance that inhibits b...
|
WO/2023/232917A1 |
The invention relates to novel compounds having the general formula (Ib) or (Ib'), (Ib) or (Ib') wherein R1, R2, R6, A3, A4, A5, X, Y and W are as described herein, composition including the compounds and methods of using the compounds.
|
WO/2023/235734A1 |
The present disclosure provides deuterated compounds and their use as sodium channel blockers in the treatment or prevention of various diseases or disorders associated with sodium channels.
|
WO/2023/235502A1 |
This disclosure relates to novel pharmaceutical compositions comprising cyclohex-2- enylidene / 3, 3 -dimethylindoline compounds; a method of treating or ameliorating a cardiovascular disease or disorder, asthma, or narcolepsy in a subje...
|